DUBLIN--(BUSINESS WIRE)--The "Global Post-Traumatic Stress Disorder Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.
The global post-traumatic stress disorder therapeutics market is projected to reach US$ 10,679.5 million by 2026, expanding at a CAGR of 4.5% from 2018 to 2026. Antidepressants are the class of promising drugs that play a stellar role in the market.
The report has been prepared based on exhaustive analysis with insights from industry professionals. The detailed study incorporates the market landscape and its growth scenarios for the forecast period from 2018 to 2026. To estimate the market size, the report ruminates branded, generic and pipeline drugs.
As per the U.S. National Comorbidity Survey Replication, around 6.8% individuals experience the ill effects of PTSD. As indicated by PTSD United, Inc. around 70% of individuals in the United States has encountered a few sorts of the shocking accident in any event once in their lives. This associate to around 223.4 million individuals.
The usage rate of healthcare services is highest in case of individuals suffering from PTSD. There are various symptoms that are commonly grouped into four different types: avoidance, changes in physical and emotional reactions, negative changes in thinking and mood, and intrusive memories that are identified in the individuals having post-traumatic stress disorder.
Based on the class of drug, the global post-traumatic stress disorder therapeutics market is segmented into antidepressants, anti-anxiety drugs, other drug classes (Alpha-1 & Alpha-2 Receptor Antagonists, Atypical Antipsychotics, and Anticonvulsants), and pipeline candidates. Rising prevalence of PTSD and the promising drug pipeline would additionally boost the post-traumatic stress disorder therapeutics market.
Key Topics Covered
Chapter 1. Preface
Chapter 2. Executive Summary
Chapter 3. Global Post-Traumatic Stress Disorder Therapeutics Market Overview, 2016-2026 (US$ Mn)
Chapter 4. Global Post-Traumatic Stress Disorder Therapeutics Market, by Drug Class, 2016-2026 (US$ Mn)
Chapter 5. Global Post-Traumatic Stress Disorder Therapeutics Market, by Geography, 2016-2026 (US$ Mn)
Chapter 6. Company Profiles
- Pfizer, Inc.
- GlaxoSmithKline plc
- Otsuka Pharmaceutical Co., Ltd
- Novartis AG
- AstraZeneca Plc
- Azevan Pharmaceuticals, Inc.
- Bionomics Ltd.
- Tonix Pharmaceuticals Holding Corp.
- Apotex, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/9jks7p/posttraumatic?w=4